Objective Pulmonary tumor thrombotic microangiopathy (PTTM) is a unique, rare and fatal form of pulmonary arterial tumor embolism. The aim of this study was to evaluate the clinical characteristics and pathological and immunohistochemical findings of PTTM. Methods Autopsy records dated between January 1983 and May 2008 in our hospital were reviewed, and those of patients who died from pulmonary tumor embolism resulting from malignant neoplasm were retrieved. The relevant tissue slides were reevaluated and examined immunohistochemically to confirm the diagnosis. Results Among 2,215 consecutive autopsy cases of carcinoma, 30 patients (1.4%) were diagnosed with definitive PTTM. The common symptom was progressive dyspnea. A hypercoagulative state was observed in all measured cases (n = 21). The chest computed tomography findings (n = 6) included consolidation, groundglass opacity, small nodules and a tree-in-bud appearance. Perfusion scans were performed in seven patients, six of whom demonstrated multiple small defects. The median survival time after the initiation of oxygen supplementation was nine days. The most frequent primary site was the stomach (n = 18 ; 60%), and the most frequent histological type was adenocarcinoma (28/30 ; 93.3%). The immunohistochemical findings for tumor cells located within the tumor emboli were positive for vascular endothelial growth factor (28/29 ; 96.6%) and tissue factor (29/29 ; 100%). Conclusion Clinicians should suspect PTTM in cancer patients who exhibit acute worsening respiratory insufficiency accompanied by a hypercoagulative state without embolism in major pulmonary arteries. The PTTM patients evaluated in our study had very poor prognoses. Vascular endothelial growth factor and tissue factor may play important roles in PTTM.
Introduction
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare form of pulmonary arterial tumor embolism. It is histologically characterized by fibrocellular intimal proliferation of small pulmonary arteries and arterioles in patients with metastatic carcinoma and is associated with the development of clinical signs of pulmonary hypertension that result in acute or subacute cor pulmonale and subacute respiratory failure (1) . The pathogenesis begins with the formation of microscopic tumor cell emboli that induce local activation of coagulation and fibrocellular intimal proliferation. Eventually, stenosis and/or occlusion occur, along with an increase in pulmonary vascular resistance that results in pulmonary hypertension, hemolytic anemia and disseminated intravas-cular coagulation. In some cases, metastatic carcinoma is not diagnosed before death, and the condition is diagnosed as pulmonary hypertension of unknown origin. However, the clinical manifestations of PTTM are not fully understood because previous literature on PTTM primarily includes pathological analyses or case reports. In this study, we reviewed autopsy cases to evaluate the clinical characteristics of PTTM and reevaluated stored tissue samples using pathological and immunohistochemical analyses.
Materials and Methods
Between January 1983 and May 2008, a total of 4,389 autopsies were performed at Toranomon Hospital in Tokyo, Japan. Among these cases, malignant neoplasms were found in 2,215 cases, including lung cancer in 575 cases and gastric cancer in 283 cases. We selected cases with malignant neoplasms in which the autopsy records described the presence of tumor microembolism in the lungs and reexamined the relevant tissue slides. PTTM was diagnosed according to the characteristic histopathological findings reported by von Herbay et al. (1) , which include the presence of tumor embolism as well as fibrocellular intimal proliferation, organization and recanalization of the arteries and arterioles within the lungs. Next, we studied the clinical data obtained from the medical charts and radiographs. Computed tomography (CT) was performed using Aquilion 16 (Toshiba Medical Systems). High-resolution CT (HRCT) was reconstructed from 1.0-mm slices obtained every 5 or 10 mm. The CT images were reevaluated independently by a pulmonary radiologist (A. K.) without prior knowledge of the clinical histories of the patients. Antibodies against vascular endothelial growth factor (VEGF)-A (VG-1 ; Delta Biolabs, Gilroy, CA, USA; at 1 : 50 dilution), tissue factor (FL295 ; Santa Cruz Biotechnology, CA, USA; at 1:200 dilution), placental growth factor (Abcam, Cambridge, UK; at 1 : 500 dilution), platelet-derived growth factor (PDGF ; Spring Bioscience, Pleasanton, CA, USA; at 1 : 100 dilution) and osteopontin (X-20 ; Santa Cruz Biotechnology; at 1 : 50 dilution) were used to perform the immunohistochemical analysis in order to evaluate the previously suggested pathogenesis of PTTM (2) (3) (4) (5) . Reports of Cases 29 and 30 have been published in Japanese journals (5, 6) . Detailed clinical information was unavailable in Case 2 because the patient died in another hospital and the autopsy only was performed in our hospital. An immunohistochemical analysis of Case 28 could not be performed because the specimens were insufficient. This retrospective study was approved by the Institutional Review Board of Toranomon Hospital (No. 525).
Results

Clinical presentation
Of the 2,215 consecutive autopsy patients with carcinoma, 170 (7.7%) had pulmonary tumor embolism, and 91 (4.1%) had fatal multiple pulmonary tumor embolism. Among the fatal cases, 30 (1.4%) patients, including 19 men and 11 women with a median age of 58.5 years (range, 34-80 years), were microscopically diagnosed with PTTM. The symptoms included progressive dyspnea (n = 26 ; 86.7%), coughing (n = 20 ; 66.7%) and hemoptysis (n = 4 ; 13.3%) ( Table 1) . Elevated serum levels of D-dimer were observed in five patients and elevated levels of fibrin degradation products (FDP) were observed in 21 patients. A diagnosis of disseminated intravascular coagulation (DIC) was made in 14 patients (46.7%). The serum VEGF level was examined in one patient (Case 30) and was found to be within the normal range (<16.5 U/mL). The median survival time following oxygen supplementation was nine days (range, 1-69 days).
All 30 patients were diagnosed with malignant cancer before death, three of whom were diagnosed with pulmonary hypertension of unknown origin. An antemortem diagnosis of PTTM was made in only one patient (Case 29) based on the findings of a CT-guided needle biopsy. The patient had received chemotherapy consisting of carboplatin and paclitaxel, which had resulted in improvement of the associated consolidation. The survival time after diagnosis of PTTM in this patient was seven months.
Physiological study
Electrocardiography demonstrated the presence of right atrial overload or ventricular hypertrophy in 13 of the 24 patients examined (Table 1) , and echocardiography demonstrated pulmonary hypertension in three of the five patients examined.
Imaging study
Chest CT was performed in six patients, three of whom were administered contrast media. The remaining three patients underwent HRCT. The CT findings of PTTM included consolidation, ground-glass opacity, small nodules and a tree-in-bud appearance (Table 1) . Contrast-enhanced CT showed negative findings for acute pulmonary embolism in three patients.
Perfusion scans were performed in seven patients, six of whom demonstrated multiple small defects. The other patient (Case 26) demonstrated a subsegmental defect. 18 F-fluorodeoxyglucose-positron emission tomography ( 18 F-FDG-PET) was performed in one patient (Case 29) who demonstrated uptake in the area of primary lung cancer and consolidation that was pathologically proven to be PTTM.
Autopsy findings
The primary site of cancer included the stomach (n= 18; 60.0%), lungs (n = 5 ; 16.7%), esophagus, liver, common bile duct, pancreas, breasts, paranasal sinus and parotid gland(n = 1 for each ; 3.3%, Table 2 ). The histological types were adenocarcinoma (n = 28 ; 93.3%), adenosquamous carcinoma (n = 1 ; 3.3%) and carcinoma (salivary duct carcinoma) ex pleomorphic adenoma (n = 1 ; 3.3%). Five lung (Figs. 1, 2) .
Discussion
To the best of our knowledge, this study is the largest case series focusing on clinical manifestations of PTTM. Although it is extremely difficult to diagnose PTTM antemortem, we believe that PTTM should be suspected in cancer patients with acute worsening respiratory insufficiency and elevated levels of D-dimer or FDP in the absence of embolism in major pulmonary arteries on enhanced CT scans. In this study, the most common symptom was progressive dyspnea, and the laboratory data indicated a hypercoagulative state, which possibly reflected the presence of tumor embolism and DIC. The prognoses in our cases were extremely poor, a finding that is consistent with those of previous series (2, 7, 8) . We used a CT-guided needle biopsy to successfully make an antemortem diagnosis of PTTM in one patient with lung cancer. This patient received standard platinum doublet chemotherapy and survived seven months. Apart from this case, only five patients were diagnosed with PTTM before death based on either video-assisted thoracoscopic surgical biopsies (n = 1) (9), right heart catheterization (n = 1) (10) or transbronchial lung biopsies (n = 3) (11-13). Three of the five patients who were diagnosed with PTTM antemortem received chemotherapy, two of whom survived for several months (9, 11) . Whether pathological changes occurred in the vascular lesions of these PTTM patients due to chemotherapy is unknown ; however, the CT findings improved following the administration of chemotherapy (6, 9) . Making an antemortem diagnosis or having a high index of suspicion of PTTM in addition to administering adequate treatment is mandatory for improving the prognoses of such patients.
Imaging studies, such as chest CT, perfusion scans and 18 F-FDG-PET, show various nonspecific findings in PTTM cases. The CT findings of PTTM include consolidation, ground-glass opacity, small nodules and a tree-in-bud appearance (9, (11) (12) (13) (14) (15) (16) . All of these findings were recognized in our study. A tree-in-bud appearance usually suggests infectious bronchiolitis ; however, this appearance is also seen in patients with PTTM resulting from tumor embolism or fibrocellular intimal proliferation in the small arteries or arterioles (14, 15) . Perfusion scans performed in PTTM patients are reported to show multiple small defects throughout the bilateral lungs (11, 17) , which was observed in six of seven patients in this study. 18 F-FDG-PET was performed in one patient (Case 29) and showed high uptake in malignant lesions and PTTM. Tashima et al. (16) also presented a case of PTTM that showed multifocal abnormal FDG uptake in both lungs.
The incidence of PTTM among all autopsy patients with carcinoma in the present study was 1.4%. This is similar to the previously reported incidence of 0.9%-3.3% (1, 18) . The most frequent primary site and histological type were the stomach and adenocarcinoma, respectively. Herbay et al. (1) (19, 20) and tumor cells (3) . Tissue factor is an initiator of coagulation in addition to factor VII, which plays a role in thrombosis, metastasis, tumor growth and tumor angiogenesis in cancers (21, 22) . The expression of VEGF and tissue factor by tumor cells has recently been confirmed in many PTTM cases (2, 4, (23) (24) (25) . In addition, PDGF and osteopontin are reported to be candidate molecules in the pathogenesis of PTTM (4, 24) . In our study, the rates of immunohistochemical positivity for tissue factor and VEGF were very high, whereas that for PDGF was relatively low. We therefore speculate that tissue factor and VEGF play important roles in the pathogenesis of PTTM.
Conclusion
PTTM patients have a very poor prognosis. It is extremely difficult to make a definitive antemortem pathological diagnosis of PTTM. PTTM should thus be suspected when cancer patients exhibit an acute worsening of respiratory insufficiency with a hypercoagulative state in the absence of embolism in major pulmonary arteries on enhanced CT scans. VEGF and tissue factor may play therefore important roles in the pathogenesis of PTTM.
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